Long-term, prospective study evaluating clinical and molecular biomarkers of EPIleptogenesiS in a genetic model of epilepsy – Tuberous sclerOsis comPlex (EPISTOP)
Epilepsy affects 1% of the world population. About 30 – 40% are drug-resistant and 50% develop serious comorbidities. 65% of all epilepsies start during infancy and the incidence is highest in the first year of life. The earlier the onset of the disease, the greater the impact on the further development, often with severe impairment of cognition and behavior.
The underlying mechanisms of epilepsy (epileptogenesis) are still unknown, because affected people usually come after the onset of seizures under medical treatment. The previous treatment concept is therefore to prohibit further seizures (secondary prophylaxis).
Recent studies show, that a large part of epileptogenesis occurs presymptomatically, and an early treatment can possibly prevent the development of epilepsy or minimize at least its extent.
Tuberous sclerosis (TS) is an excellent clinical model to investigate epileptogenesis, because 71% of TS – patients develop epilepsy in the first year of life.
In the context of the EPISTOP-study, risk factors and biomarkers for genesis and progress of epilepsy in infants should be identified. These new targets might prevent or positively influence the course of the disease. During this project new ways and treatment-guidelines should be established and thus contributing to improving the quality of patient care and life.
MedUni Vienna Researchers
The Medical University of Vienna is project partner under the leadership of Univ. Prof. Dr. Martha Feucht
Angelika Mühlebner-Fahrngruber / Sharon Samueli / Theresa Scholl
Project Coordinator: Prof. Sergiusz Jóźwiak / Instytut "Pomnik-Centrum Zdrowia Dziecka", Warschau, Polen.
13 project partners
Patho-physiology and therapy of epilepsy and epileptiform disorders /
Collaborative Project (large-scale integrating project)
|Project duration||11.2013 - 10.2018|
|Funding volume, Medical University of Vienna||535.916 €|
|Funding volume, total||9,451.675 €|